Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
Lancet. 2021.
PMID: 34863358
Free PMC article.
Clinical Trial.
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J, Bickerstaff M, Stackpoole M, Khan UT, Carruthers S, Oates M, Lin K, Coupland SE, Menon G, Kalakonda N, McCarthy H, Bloor A, Schuh A, Duncombe A, Dearden C, Fegan C, Kennedy B, Walewska R, Marshall S, Fox CP, Hillmen P.
Pettitt AR, et al. Among authors: stackpoole m.
Haematologica. 2020 Dec 1;105(12):2868-2871. doi: 10.3324/haematol.2019.230805.
Haematologica. 2020.
PMID: 33256390
Free PMC article.
No abstract available.
Item in Clipboard
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group.
Munro APS, et al.
Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.
Lancet Infect Dis. 2022.
PMID: 35550261
Free PMC article.
Clinical Trial.
Item in Clipboard
Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations.
Walker LE, Stackpoole M, Hodge D, FitzGerald R.
Walker LE, et al. Among authors: stackpoole m.
Br J Clin Pharmacol. 2024 May 9. doi: 10.1111/bcp.16073. Online ahead of print.
Br J Clin Pharmacol. 2024.
PMID: 38725250
Item in Clipboard
Cite
Cite